910656-45-0

Basic information

• Product Name: Butanoic acid, 2-hydroxy-2-(trifluoroMethyl)-, hydrazide
• Synonyms: Butanoic acid, 2-hydroxy-2-(trifluoroMethyl)-, hydrazide
• CAS NO: 910656-45-0
• Molecular Formula: C5H9F3N2O2
• Molecular Weight: 186.1323696
• EINECS: -0
• Mol File: 910656-45-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Butanoic acid, 2-hydroxy-2-(trifluoroMethyl)-, hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 2-hydroxy-2-(trifluoroMethyl)-, hydrazide(910656-45-0)
• EPA Substance Registry System: Butanoic acid, 2-hydroxy-2-(trifluoroMethyl)-, hydrazide(910656-45-0)

Safety Data

• Hazardous Substances Data: 910656-45-0(Hazardous Substances Data)

Downstream Products

• 1229617-81-5 C₂₂H₁₉F₄N₃O₄S 

Relevant articles and documents

INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.

A practical synthesis of 5-lipoxygenase inhibitor MK-0633

Practical, chromatography-free syntheses of 5-lipoxygenase inhibitor MK-0633 p-toluenesulfonate (1) are described. The first route used an asymmetric zincate addition to ethyl 2,2,2-trifluoropyruvate followed by 1,3,4-oxadiazole formation and reductive amination as key steps. An improved second route features an inexpensive diastereomeric salt resolution of vinyl hydroxy-acid 22 followed by a robust end-game featuring a through-process hydrazide acylation/1,3,4-oxadiazole ring closure/salt formation sequence to afford MK-0633 p-toluenesulfonate (1).

THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR

The instant invention provides compounds of Formula (Ia) which are leukotriene biosynthesis inhibitors, wherein X is O or S, Y is O, S, -NR6-CHR7- or -NR8-C(O)- and A is selected from 5-membered aromatic heterocyclic ring, 6-membered aromatic heterocyclic ring, naphthelenic or heterobicyclic aromatic ring system, phenyl and benzyl. A is optionally mono- or disubstituted. Compounds of Formula (Ia) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.